open access

Vol 8, No 4 (2004)
REVIEV
Published online: 2004-07-22
Get Citation

The role of renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis. Impact on endothelial cells and accumulation of mononuclear leukocytes in the vascular wall

Danuta Zapolska-Downar, Anita Kośmider
Nadciśnienie tętnicze 2004;8(4):279-291.

open access

Vol 8, No 4 (2004)
REVIEV
Published online: 2004-07-22

Abstract

Atherosclerosis is presently considered to be a type of chronic inflammatory disease in which development endothelial cell dysfunction, oxidative stress, and the fibroproliferative process within the vascular wall play very important role. Arterial hypertension, which is one of the major risk factors of atherosclerosis, may exert an important effect on many mechanisms significantly contributing to the development and progress of atherosclerosis. The article discusses in detail the role of endothelial cell dysfunction in atherosclerosis pathogenesis and mechanisms responsible for selective accumulation of mononuclear leukocytes within the vascular wall and thus for inflammation existing there. Subsequently, on the basis of the results of experimental and clinical studies, the possibilities of participation of hypertension, and in particular of angiotensin II, in these stages of development of atherosclerosis so significant for this disorder have been discussed. Morever, the article discusses how angiotensin II contributes to the intensity of inflammatory response and destabilisation of the atherosclerotic plaque and thus to the occurrence of clinical complication of atherosclerosis.

Abstract

Atherosclerosis is presently considered to be a type of chronic inflammatory disease in which development endothelial cell dysfunction, oxidative stress, and the fibroproliferative process within the vascular wall play very important role. Arterial hypertension, which is one of the major risk factors of atherosclerosis, may exert an important effect on many mechanisms significantly contributing to the development and progress of atherosclerosis. The article discusses in detail the role of endothelial cell dysfunction in atherosclerosis pathogenesis and mechanisms responsible for selective accumulation of mononuclear leukocytes within the vascular wall and thus for inflammation existing there. Subsequently, on the basis of the results of experimental and clinical studies, the possibilities of participation of hypertension, and in particular of angiotensin II, in these stages of development of atherosclerosis so significant for this disorder have been discussed. Morever, the article discusses how angiotensin II contributes to the intensity of inflammatory response and destabilisation of the atherosclerotic plaque and thus to the occurrence of clinical complication of atherosclerosis.
Get Citation

Keywords

atherosclerosis; hypertension; angiotensin II; endothelial cell dysfunction; mononuclear cell accumulation; inflammation

About this article
Title

The role of renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis. Impact on endothelial cells and accumulation of mononuclear leukocytes in the vascular wall

Journal

Arterial Hypertension

Issue

Vol 8, No 4 (2004)

Pages

279-291

Published online

2004-07-22

Bibliographic record

Nadciśnienie tętnicze 2004;8(4):279-291.

Keywords

atherosclerosis
hypertension
angiotensin II
endothelial cell dysfunction
mononuclear cell accumulation
inflammation

Authors

Danuta Zapolska-Downar
Anita Kośmider

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl